Its expression is down-regulated in serous carcinomas, in contrast to ovarian serous borderline tumors and action through uncoupling activation of the RAS-RAF-MEK-ERK-MAPK pathway, which is a typical survival signal pathway in cancers [48]. The gene discussed is MAP2K7; the disease is serous adenocarcinoma.